Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jasper Therapeutics ( (JSPR) ) has provided an update.
On July 8, 2025, Jasper Therapeutics announced a corporate reorganization to extend its cash runway, which includes reducing its workforce by approximately 50% and focusing on its briquilimab clinical development programs in chronic urticaria. The reorganization involves halting other clinical and preclinical programs and the departure of Dr. Edwin Tucker as Chief Medical Officer, with Dr. Daniel Adelman stepping in as Acting Chief Medical Officer. The company estimates incurring $1.8 million to $2.2 million in severance-related expenditures through September 30, 2025. This strategic move aims to streamline operations and concentrate resources on briquilimab, which has shown promising results in clinical studies.
The most recent analyst rating on (JSPR) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on Jasper Therapeutics stock, see the JSPR Stock Forecast page.
Spark’s Take on JSPR Stock
According to Spark, TipRanks’ AI Analyst, JSPR is a Underperform.
Jasper Therapeutics faces significant financial challenges with a lack of revenue and ongoing losses, leading to a low financial performance score. The technical analysis indicates bearish momentum, and the negative valuation metrics highlight the stock’s unattractiveness. Without earnings call data or notable corporate events, the overall outlook remains concerning.
To see Spark’s full report on JSPR stock, click here.
More about Jasper Therapeutics
Jasper Therapeutics is a clinical-stage biotechnology company focused on developing briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). Briquilimab is designed to inhibit signaling through the KIT receptor, leading to the depletion of mast cells and addressing the inflammatory response in these diseases.
Average Trading Volume: 512,213
Technical Sentiment Signal: Sell
Current Market Cap: $45.67M
See more insights into JSPR stock on TipRanks’ Stock Analysis page.